Tilray | TRLY - Gross Profit On Sales


Tilray reported $57.47M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
Acasti Pharma USD 75K 30K Mar/2021
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Aurora Cannabis CAD 29.79M 16.83M Mar/2026
Avita Medical AUD 14.31M 639K Dec/2025
Canopy Growth CAD 8.26M 13.2M Mar/2026
Cronos Group USD 28.45M 9.3M Jun/2026
Dianthus Therapeutics USD 463K 179K Mar/2026
Divis Laboratories Ltd INR 19.61B 2.49B Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
IQVIA Holdings USD 1.44B 368M Jun/2026
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
Moderna USD -566M 792M Mar/2026
Organigram Holdings CAD 16.41M 6.91M Mar/2026
Organon & Co USD 847M 64M Jun/2026
Revvity USD 416.87M 29.21M Jun/2026
Tectonic Therapeutic USD 0 0 Mar/2025
Tilray USD 57.47M 10.16M Jun/2025
Viatris USD 1.57B 193.9M Jun/2026
Xeris Pharmaceuticals USD 72.55M 404K Mar/2026
Zealand Pharma A/S 34M 34.92M Mar/2026